Reported Sunday, Australia's TGA Approves Specialised Therapeutics' NIKTIMVO As First-In-Class CSF-1R Blocking Antibody For Chronic Graft-Versus-Host Disease

Incyte Corporation

Incyte Corporation

INCY

0.00
  • NIKTIMVO (axatilimab) approved by the Therapeutic Goods Administration (TGA) under Priority Review for the treatment of eligible Australian patients with chronic graft-versus-host disease[2]
  • Australia becomes the first country to obtain Marketing Authorisation for NIKTIMVO since approval by the US FDA[3]
  • Australian-led research played key role in the development of NIKTIMVO, a first-in-class novel colony stimulating factor-1 receptor (CSF-1R) blocking antibody.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.